Antibodies Market Report 2024

This Antibodies market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The antibodies market size has grown rapidly in recent years. It will grow from $249.13 billion in 2023 to $286.81 billion in 2024 at a compound annual growth rate (CAGR) of 15.1%. The growth observed in the historic period can be attributed to an increase in the prevalence of chronic diseases, a rise in the number of clinical trials, an expansion of therapeutic areas, growing awareness of personalized medicine, and an increase in diagnostic applications.

The antibodies market size is expected to see rapid growth in the next few years. It will grow to $504.99 billion in 2028 at a compound annual growth rate (CAGR) of 15.2%. The growth anticipated during the forecast period can be attributed to a rise in cancer research, expanding applications of immunotherapy, increasing use of monoclonal antibodies, a growing number of clinical trials, and greater adoption of precision medicine. Key trends for the forecast period include the adoption of advanced biomanufacturing technologies, advancements in antibody engineering, the integration of high-throughput screening methods, the use of next-generation sequencing technologies, and the development of novel delivery systems.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the antibodies market. Autoimmune diseases are conditions where the immune system mistakenly targets and damages its own tissues, including disorders such as rheumatoid arthritis, lupus, and multiple sclerosis. The rising incidence of autoimmune diseases is linked to environmental factors, genetic predispositions, and lifestyle changes. Antibodies are critical in this context as they target and neutralize specific immune cells or inflammatory molecules that erroneously attack the body's tissues, thus reducing inflammation and alleviating symptoms. For example, in May 2024, the Multiple Sclerosis International Federation, a UK-based non-profit organization, reported an increase in the global number of people with multiple sclerosis from 2.8 million in 2020 to 2.9 million in 2023. Consequently, the growing prevalence of autoimmune diseases is contributing to the expansion of the antibodies market.

Leading companies in the antibodies market are focusing on developing validated antibodies to improve accuracy and ensure consistent results in both diagnostics and therapeutics. Validated antibodies are those that have undergone testing and confirmation for accuracy and specificity in detecting target proteins. This validation enhances the reliability of research findings and the effectiveness of antibody-based products. For instance, in March 2024, Bio-Rad Laboratories, a US-based life science research and clinical diagnostics company, introduced Celselect slides validated antibodies designed for rare cell and circulating tumor cell (CTC) enumeration. This advancement enhances the study of tumor heterogeneity and disease progression. The validated antibodies, compatible with Bio-Rad’s Celselect Slides Enumeration Stain Kits, facilitate precise CTC detection, representing a significant advancement in cancer research and diagnostics.

In June 2024, Johnson & Johnson Services Inc., a US-based pharmaceutical and medical device company, acquired Proteologix Inc. for $850 million. This acquisition aims to strategically advance Johnson & Johnson’s development of innovative treatments for immune-mediated diseases by integrating Proteologix’s advanced bispecific antibodies. The acquisition aligns with Johnson & Johnson’s objective to enhance its immunology portfolio with effective and optimized therapies for conditions such as atopic dermatitis and asthma. Proteologix Inc. is a US-based provider of antibodies.

Major companies operating in the antibodies market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Alexion Pharmaceuticals Inc., Incyte Corporation, Kyowa Kirin Co Ltd, Ultragenyx Pharmaceutical Inc, Xencor Inc., MacroGenics Inc., ImmunoGen Inc., Sorrento Therapeutics Inc., Beam Therapeutics Inc., SAB Biotherapeutics Inc., bluebird bio Inc., Iovance Biotherapeutics Inc.

North America was the largest region in the antibodies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Antibodies are proteins produced by the immune system in response to foreign substances such as bacteria or viruses. They recognize and attach to antigens, which are specific molecules found on the surface of these invaders. This attachment either neutralizes the pathogen or signals other immune cells to destroy it. Antibodies are a crucial part of the adaptive immune system, with each one targeting a specific antigen.

The main product types in the antibodies market include monoclonal antibodies, polyclonal antibodies, and antibody-drug conjugates. Monoclonal antibodies are lab-created molecules engineered to specifically target certain proteins or antigens within the body. These products are used for various disease indications, such as cardiovascular diseases, central nervous system (CNS) disorders, cancer, autoimmune diseases, and more, and are utilized by hospitals, long-term care facilities, research institutions, and others.

The antibodies market research report is one of a series of new reports that provides antibodies market statistics, including the antibodies industry global market size, regional shares, competitors with antibodies market share, detailed antibodies market segments, market trends, and opportunities, and any further data you may need to thrive in the antibodies industry. These antibodies market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antibodies market consists of sales of recombinant antibodies, antibody-based assays, bispecific antibodies, single domain antibodies, humanized antibodies, and diagnostic kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.